Your browser doesn't support javascript.
loading
Hypertension Canada's 2016 Canadian Hypertension Education Program Guidelines for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension.
Leung, Alexander A; Nerenberg, Kara; Daskalopoulou, Stella S; McBrien, Kerry; Zarnke, Kelly B; Dasgupta, Kaberi; Cloutier, Lyne; Gelfer, Mark; Lamarre-Cliche, Maxime; Milot, Alain; Bolli, Peter; Tremblay, Guy; McLean, Donna; Tobe, Sheldon W; Ruzicka, Marcel; Burns, Kevin D; Vallée, Michel; Prasad, G V Ramesh; Lebel, Marcel; Feldman, Ross D; Selby, Peter; Pipe, Andrew; Schiffrin, Ernesto L; McFarlane, Philip A; Oh, Paul; Hegele, Robert A; Khara, Milan; Wilson, Thomas W; Penner, S Brian; Burgess, Ellen; Herman, Robert J; Bacon, Simon L; Rabkin, Simon W; Gilbert, Richard E; Campbell, Tavis S; Grover, Steven; Honos, George; Lindsay, Patrice; Hill, Michael D; Coutts, Shelagh B; Gubitz, Gord; Campbell, Norman R C; Moe, Gordon W; Howlett, Jonathan G; Boulanger, Jean-Martin; Prebtani, Ally; Larochelle, Pierre; Leiter, Lawrence A; Jones, Charlotte; Ogilvie, Richard I.
Afiliação
  • Leung AA; Division of Endocrinology and Metabolism, Department of Medicine, University of Calgary, Calgary, Alberta, Canada. Electronic address: aacleung@ucalgary.ca.
  • Nerenberg K; Department of Medicine and Department of Obstetrics and Gynecology, University of Calgary, Calgary, Alberta, Canada.
  • Daskalopoulou SS; Divisions of General Internal Medicine, Clinical Epidemiology and Endocrinology, Department of Medicine, McGill University, McGill University Health Centre, Montreal, Quebec, Canada.
  • McBrien K; Departments of Family Medicine and Community Health Sciences, Institute for Public Health, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
  • Zarnke KB; Division of General Internal Medicine, University of Calgary, Calgary, Alberta, Canada.
  • Dasgupta K; Divisions of General Internal Medicine, Clinical Epidemiology and Endocrinology, Department of Medicine, McGill University, McGill University Health Centre, Montreal, Quebec, Canada.
  • Cloutier L; Université du Québec à Trois-Rivières, Trois-Rivières, Quebec, Canada.
  • Gelfer M; Department of Family Medicine, University of British Columbia, Copeman Healthcare Centre, Vancouver, British Columbia, Canada.
  • Lamarre-Cliche M; Institut de Recherches Cliniques de Montréal, Université de Montréal, Montréal, Quebec, Canada.
  • Milot A; Department of Medicine, Université Laval, Québec, Quebec, Canada.
  • Bolli P; Ambulatory Internal Medicine Teaching Clinic, St Catharines, Ontario, Canada.
  • Tremblay G; CHU-Québec-Hopital St Sacrement, Québec, Quebec, Canada.
  • McLean D; University of Alberta, Edmonton, Alberta, Canada.
  • Tobe SW; University of Toronto, Toronto, Ontario, Canada.
  • Ruzicka M; Division of Nephrology, Department of Medicine, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, Canada.
  • Burns KD; Division of Nephrology, Department of Medicine, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, Canada.
  • Vallée M; Hôpital Maisonneuve-Rosemont, Université de Montréal, Montréal, Quebec, Canada.
  • Prasad GV; University of Toronto, Toronto, Ontario, Canada.
  • Lebel M; Department of Medicine, Université Laval, Québec, Quebec, Canada.
  • Feldman RD; Discipline of Medicine, Memorial University of Newfoundland, St John's, Newfoundland and Labrador, Canada.
  • Selby P; Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada.
  • Pipe A; University of Ottawa Heart Institute, Ottawa, Ontario, Canada.
  • Schiffrin EL; Department of Medicine and Lady Davis Institute for Medical Research, Jewish General Hospital, McGill University, Montreal, Quebec, Canada.
  • McFarlane PA; Division of Nephrology, St Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.
  • Oh P; University Health Network, University of Toronto, Toronto, Ontario, Canada.
  • Hegele RA; Departments of Medicine (Division of Endocrinology) and Biochemistry, Western University, London, Ontario, Canada.
  • Khara M; Vancouver Coastal Health Addiction Services, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
  • Wilson TW; Department of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.
  • Penner SB; Department of Internal Medicine, University of Manitoba, Winnipeg, Manitoba, Canada.
  • Burgess E; Department of Medicine, University of Calgary, Calgary, Alberta, Canada.
  • Herman RJ; Division of General Internal Medicine, University of Calgary, Calgary, Alberta, Canada.
  • Bacon SL; Department of Exercise Science, Concordia University, and Montreal Behavioural Medicine Centre, Hôpital du Sacré-Coeur de Montréal, Montréal, Quebec, Canada.
  • Rabkin SW; Vancouver Hospital, University of British Columbia, Vancouver, British Columbia, Canada.
  • Gilbert RE; Division of Endocrinology, St Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.
  • Campbell TS; Department of Psychology, University of Calgary, Calgary, Alberta, Canada.
  • Grover S; Division of Clinical Epidemiology, Montreal General Hospital, Montreal, Quebec, Canada.
  • Honos G; University of Montreal, Montreal, Quebec, Canada.
  • Lindsay P; Best Practices and Performance, Heart and Stroke Foundation, Toronto, Ontario, Canada.
  • Hill MD; Department of Clinical Neurosciences, Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada.
  • Coutts SB; Departments of Clinical Neurosciences and Radiology, Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada.
  • Gubitz G; Division of Neurology, Halifax Infirmary, Dalhousie University, Halifax, Nova Scotia, Canada.
  • Campbell NR; Medicine, Community Health Sciences, Physiology and Pharmacology, Libin Cardiovascular Institute of Alberta, University of Calgary, Calgary, Alberta, Canada.
  • Moe GW; St Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.
  • Howlett JG; Departments of Medicine and Cardiac Sciences, University of Calgary, Calgary, Alberta, Canada.
  • Boulanger JM; Charles LeMoyne Hospital Research Centre, Sherbrooke University, Sherbrooke, Quebec, Canada.
  • Prebtani A; McMaster University, Hamilton, Ontario, Canada.
  • Larochelle P; Institut de Recherches Cliniques de Montréal, Université de Montréal, Montréal, Quebec, Canada.
  • Leiter LA; Keenan Research Centre in the Li Ka Shing Knowledge Institute of St Michael's Hospital, and University of Toronto, Toronto, Ontario, Canada.
  • Jones C; University of British Columbia, Vancouver, British Columbia, Canada.
  • Ogilvie RI; University Health Network, Departments of Medicine and Pharmacology, University of Toronto, Toronto, Ontario, Canada.
Can J Cardiol ; 32(5): 569-88, 2016 05.
Article em En | MEDLINE | ID: mdl-27118291
Hypertension Canada's Canadian Hypertension Education Program Guidelines Task Force provides annually updated, evidence-based recommendations to guide the diagnosis, assessment, prevention, and treatment of hypertension. This year, we present 4 new recommendations, as well as revisions to 2 previous recommendations. In the diagnosis and assessment of hypertension, automated office blood pressure, taken without patient-health provider interaction, is now recommended as the preferred method of measuring in-office blood pressure. Also, although a serum lipid panel remains part of the routine laboratory testing for patients with hypertension, fasting and nonfasting collections are now considered acceptable. For individuals with secondary hypertension arising from primary hyperaldosteronism, adrenal vein sampling is recommended for those who are candidates for potential adrenalectomy. With respect to the treatment of hypertension, a new recommendation that has been added is for increasing dietary potassium to reduce blood pressure in those who are not at high risk for hyperkalemia. Furthermore, in selected high-risk patients, intensive blood pressure reduction to a target systolic blood pressure ≤ 120 mm Hg should be considered to decrease the risk of cardiovascular events. Finally, in hypertensive individuals with uncomplicated, stable angina pectoris, either a ß-blocker or calcium channel blocker may be considered for initial therapy. The specific evidence and rationale underlying each of these recommendations are discussed. Hypertension Canada's Canadian Hypertension Education Program Guidelines Task Force will continue to provide annual updates.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Determinação da Pressão Arterial / Hipertensão / Anti-Hipertensivos Tipo de estudo: Diagnostic_studies / Etiology_studies / Guideline / Risk_factors_studies Limite: Humans País/Região como assunto: America do norte Idioma: En Revista: Can J Cardiol Assunto da revista: CARDIOLOGIA Ano de publicação: 2016 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Determinação da Pressão Arterial / Hipertensão / Anti-Hipertensivos Tipo de estudo: Diagnostic_studies / Etiology_studies / Guideline / Risk_factors_studies Limite: Humans País/Região como assunto: America do norte Idioma: En Revista: Can J Cardiol Assunto da revista: CARDIOLOGIA Ano de publicação: 2016 Tipo de documento: Article